109 related articles for article (PubMed ID: 16027405)
1. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects.
Kim KA; Park PW; Kim HK; Ha JM; Park JY
J Clin Pharmacol; 2005 Aug; 45(8):941-6. PubMed ID: 16027405
[TBL] [Abstract][Full Text] [Related]
2. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.
Kim KA; Park PW; Kim KR; Park JY
Br J Clin Pharmacol; 2007 Mar; 63(3):339-45. PubMed ID: 16981900
[TBL] [Abstract][Full Text] [Related]
3. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
Tornio A; Niemi M; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2008 Jan; 36(1):73-80. PubMed ID: 17913794
[TBL] [Abstract][Full Text] [Related]
4. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.
Pedersen RS; Damkier P; Brosen K
Br J Clin Pharmacol; 2006 Dec; 62(6):682-9. PubMed ID: 16856883
[TBL] [Abstract][Full Text] [Related]
5. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.
Niemi M; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2004 Sep; 76(3):239-49. PubMed ID: 15371985
[TBL] [Abstract][Full Text] [Related]
6. The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.
Naik H; Wu JT; Palmer R; McLean L
Br J Clin Pharmacol; 2012 Aug; 74(2):327-35. PubMed ID: 22242967
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J; Thomas S; Bauer S; Tomalik-Scharte D; Hering U; Doroshyenko O; Jetter A; Stehle S; Tsahuridu M; Meineke I; Brockmöller J; Fuhr U
Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
[TBL] [Abstract][Full Text] [Related]
8. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
Mistry GC; Bergman AJ; Luo WL; Cilissen C; Haazen W; Davies MJ; Gottesdiener KM; Wagner JA; Herman GA
J Clin Pharmacol; 2007 Feb; 47(2):159-64. PubMed ID: 17244766
[TBL] [Abstract][Full Text] [Related]
9. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.
Park JY; Kim KA; Kang MH; Kim SL; Shin JG
Clin Pharmacol Ther; 2004 Mar; 75(3):157-62. PubMed ID: 15001966
[TBL] [Abstract][Full Text] [Related]
10. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.
Park JY; Kim KA; Shin JG; Lee KY
Br J Clin Pharmacol; 2004 Oct; 58(4):397-402. PubMed ID: 15373932
[TBL] [Abstract][Full Text] [Related]
11. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
12. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.
Kosoglou T; Kumar B; Statkevich P; Schiller JE; Kantesaria B; Hanson ME; Sisk CM; Cutler DL
Clin Pharmacol Drug Dev; 2015 Jan; 4(1):56-62. PubMed ID: 27128003
[TBL] [Abstract][Full Text] [Related]
13. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
[TBL] [Abstract][Full Text] [Related]
14. Effect of pentoxifylline on the pharmacokinetics of rosiglitazone in Wistar rats.
Varanasi KK; Potharaju S; Rajak S; Veeraraghavan S; Mallick P; Vakkalanka SK
Methods Find Exp Clin Pharmacol; 2008 Sep; 30(7):537-42. PubMed ID: 18985182
[TBL] [Abstract][Full Text] [Related]
15. Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.
Schwartz JI; Stroh M; Gao B; Liu F; Rosko K; Zajic S; Meehan AJ; Ruckle J; Lai E; Wagner JA
Cardiovasc Ther; 2009; 27(4):239-45. PubMed ID: 19903187
[TBL] [Abstract][Full Text] [Related]
16. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.
Hruska MW; Amico JA; Langaee TY; Ferrell RE; Fitzgerald SM; Frye RF
Br J Clin Pharmacol; 2005 Jan; 59(1):70-9. PubMed ID: 15606443
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
[TBL] [Abstract][Full Text] [Related]
18. Effect of rifampicin on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ
Br J Clin Pharmacol; 2006 Jan; 61(1):70-8. PubMed ID: 16390353
[TBL] [Abstract][Full Text] [Related]
19. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients.
Aramwit P; Supasyndh O; Sriboonruang T
J Clin Pharm Ther; 2008 Dec; 33(6):685-90. PubMed ID: 19138247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]